-
1.发明授权Method for preparing a biodegradable polymer microsphere containing a glucose-regulating peptide 失效制备含有葡萄糖调节肽的可生物降解聚合物微球的方法公开(公告)号：US08282990B2
公开(公告)日：2012-10-09
申请号：US12595434
申请日：2008-04-18
申请人： Hyun Hee Kwak , Ghun II Lee , Yong Man Park , Mi Kyung Son , Hi Chang Yang , Tae Hyoung Kim , Yoon Ji Kim , Byong Moon Kim , Sung Hee Lee , Soo Hyung Kang , Moohi Yoo
发明人： Hyun Hee Kwak , Ghun II Lee , Yong Man Park , Mi Kyung Son , Hi Chang Yang , Tae Hyoung Kim , Yoon Ji Kim , Byong Moon Kim , Sung Hee Lee , Soo Hyung Kang , Moohi Yoo
CPC分类号： A61K9/1647 , A61K38/26 , Y02A50/465
摘要： Disclosed are biodegradable microspheres, capable of releasing a glucose-regulating peptide in a controlled manner, comprising a biodegradable polymer carrier with the glucose -regulating peptide encapsulated therein, and methods for the preparation thereof. In addition to ensuring high encapsulation efficiency and high stability of the encapsulated drug, the microspheres shows neither an initial burst effect nor incomplete release and allows the zero -order release of drugs over a prolonged period of time, thus improving the therapeutic effect of the drug.
摘要翻译： 公开了能够以受控方式释放葡萄糖调节肽的生物可降解微球，其包含其中包封有葡萄糖调节肽的生物可降解聚合物载体及其制备方法。 除了确保包封药物的高封装效率和高稳定性之外，微球体既不显示初始爆发效应也不显示不完全释放，并允许药物在一段较长时间内零次释放，从而改善药物的治疗效果 。
-
2.发明授权Method for treating asthma and chronic obstructive pulmonary disease (COPD) comprising administering FGF2 有权治疗哮喘和慢性阻塞性肺疾病（COPD）的方法，包括给予FGF2公开(公告)号：US08030274B2
公开(公告)日：2011-10-04
申请号：US11568896
申请日：2005-05-12
申请人： Yoon-Keum Kim , Soo Hyung Kang , Byong Moon Kim , Miwon Son
发明人： Yoon-Keum Kim , Soo Hyung Kang , Byong Moon Kim , Miwon Son
CPC分类号： A01K67/0275 , A01K2207/05 , A01K2207/10 , A01K2217/07 , A01K2217/203 , A01K2227/105 , A01K2267/0368 , A61K38/1825 , C07K14/52 , C07K14/5437 , C07K14/57 , C12N15/8509
摘要： The present invention relates an agent comprising FGF2 (Fibroblast Growth Factor-2 or basic Fibroblast Growth Factor (bFGF)) as an effective ingredient for treatment or prevention of Asthma and Chronic Obstructive Pulmonary Disease (COPD). Also, The present invention relates Th1 asthma and COPD mouse animal model induced by Ovalbumin and double strand RNA. The therapeutic agent comprising FGF2 of the present invention can be used for treatment or prevention for airway fibrosis, airway inflammation, airway hyperresponsiveness, airway remodeling, asthma and COPD. Also, Th1 asthma and COPD mice animal model induced by Ovalbumin and double strand RNA can be used for development of therapeutic agent for asthma and COPD.
摘要翻译： 本发明涉及包含FGF2（成纤维细胞生长因子-2或碱性成纤维细胞生长因子（bFGF））作为治疗或预防哮喘和慢性阻塞性肺疾病（COPD）的有效成分的药剂。 此外，本发明涉及由卵白蛋白和双链RNA诱导的Th1哮喘和COPD小鼠动物模型。 包含本发明的FGF2的治疗剂可用于治疗或预防气道纤维化，气道炎症，气道高反应性，气道重塑，哮喘和COPD。 此外，Th1哮喘和COPD小鼠由卵白蛋白和双链RNA诱导的动物模型可用于开发哮喘和COPD治疗剂。
-
3.发明申请BIODEGRADABLE MICROSPHERE COMPOSITION SUITABLE FOR THE CONTROLLED RELEASE OF GLUCOSE CONTROLLING PEPTIDE AND FORMULATION THEREOF 失效生物可降解微生物组合物，适用于控制葡萄糖控制肽及其制剂的释放公开(公告)号：US20100129459A1
公开(公告)日：2010-05-27
申请号：US12595434
申请日：2008-04-18
申请人： Hyun Hee Kwak , Ghun Lee, II , Yong Man Park , Mi Kyung Son , Hi Chang Yang , Tae Hyoung Kim , Yoon Ji Kim , Byong Moon Kim , Sung Hee Lee , Soo Hyung Kang , Moohi Yoo
发明人： Hyun Hee Kwak , Ghun Lee, II , Yong Man Park , Mi Kyung Son , Hi Chang Yang , Tae Hyoung Kim , Yoon Ji Kim , Byong Moon Kim , Sung Hee Lee , Soo Hyung Kang , Moohi Yoo
CPC分类号： A61K9/1647 , A61K38/26 , Y02A50/465
摘要： Disclosed are biodegradable microspheres, capable of releasing a glucose-regulating peptide in a controlled manner, comprising a biodegradable polymer carrier with the glucose-regulating peptide encapsulated therein, and methods for the preparation thereof. In addition to ensuring high encapsulation efficiency and high stability of the encapsulated drug, the microspheres shows neither an initial burst effect nor incomplete release and allows the zero-order release of drugs over a prolonged period of time, thus improving the therapeutic effect of the drug.
摘要翻译： 公开了能够以受控方式释放葡萄糖调节肽的生物可降解微球，其包含其中包含葡萄糖调节肽的生物可降解聚合物载体及其制备方法。 除了确保包封药物的高封装效率和高稳定性之外，微球体既不显示初始爆发效应也不显示不完全释放，并允许药物在较长时间内零次释放，从而改善药物的治疗效果 。
-
公开(公告)号：US20090117077A1
公开(公告)日：2009-05-07
申请号：US12300580
申请日：2006-05-12
申请人： Yeong-Woo Jo , Won-Young Yoo , Hyun-Kyu Jeon , Yun-Kyu Choi , Hye-In Jang , Byong-Moon Kim , Sung-Hee Lee , Soo-Hyung Kang
发明人： Yeong-Woo Jo , Won-Young Yoo , Hyun-Kyu Jeon , Yun-Kyu Choi , Hye-In Jang , Byong-Moon Kim , Sung-Hee Lee , Soo-Hyung Kang
CPC分类号： A61K38/212 , A61K47/60 , C08G65/329 , C08G65/33337 , C08L2203/02
摘要： The present invention relates to three-branched polyethylene glycol-interferon alpha conjugate of general formula (1) wherein polyethylene glycol has an average molecular weight of from 400 to 45,000 daltons, and a pharmaceutical composition comprising the same. The bioactive polyethylene glycol-interferon alpha conjugate of general formula (1) has antiviral and antitumoral activities, improved yield and purity by high reactivity in the reaction, and the effects to increase the half-life in blood remarkably, and to minimize the decreases in biological activity of interferon.
摘要翻译： 本发明涉及通式（1）的三支链聚乙二醇 - 干扰素α缀合物，其中聚乙二醇具有400至45,000道尔顿的平均分子量，以及包含其的药物组合物。 通式（1）的生物活性聚乙二醇 - 干扰素α结合物具有抗病毒和抗肿瘤活性，通过反应高反应性提高产率和纯度，并且显着增加血液半衰期的作用，并使减少 干扰素的生物活性。
-
公开(公告)号：US08329191B2
公开(公告)日：2012-12-11
申请号：US12515122
申请日：2006-11-22
申请人： Yeong-Woo Jo , Won-Young Yoo , Hyun-Kyu Jeon , Yun-Kyu Choi , Hye-In Jang , Byong-Moon Kim , Sung-Hee Lee , Soo-Hyung Kang , Moo-Hi Yoo
发明人： Yeong-Woo Jo , Won-Young Yoo , Hyun-Kyu Jeon , Yun-Kyu Choi , Hye-In Jang , Byong-Moon Kim , Sung-Hee Lee , Soo-Hyung Kang , Moo-Hi Yoo
CPC分类号： A61K9/0019 , A61K31/77 , A61K47/60
摘要： The present invention relates to three-branched PEG-G-CSF conjugate of general formula (1) in which the bonding ratio of three-branched polyethylene glycol (PEG) and G-CSF is 1:1 (mol/mol), wherein PEG has an average molecular weight of from 200 to 45,000 daltons; a pharmaceutical composition comprising the same, and a preparing method thereof.
摘要翻译： 本发明涉及三分支PEG-G-CSF缀合物，其中三分支聚乙二醇（PEG）和G-CSF的键合比为1:1（mol / mol），其中PEG 平均分子量为200至45,000道尔顿; 包含其的药物组合物及其制备方法。
-
公开(公告)号：US20100105616A1
公开(公告)日：2010-04-29
申请号：US12515122
申请日：2006-11-22
申请人： Yeong-Woo Jo , Won-Young Yoo , Hyun-Kyu Jeon , Yun-kyu Choi , Hye-In Jang , Byong-Moon Kim , Sung-Hee Lee , Soo-Hyung Kang , Moo-Hi Yoo
发明人： Yeong-Woo Jo , Won-Young Yoo , Hyun-Kyu Jeon , Yun-kyu Choi , Hye-In Jang , Byong-Moon Kim , Sung-Hee Lee , Soo-Hyung Kang , Moo-Hi Yoo
IPC分类号： A61K38/18 , C07K14/475 , A61P7/00
CPC分类号： A61K9/0019 , A61K31/77 , A61K47/60
摘要： The present invention relates to three-branched PEG-G-CSF conjugate of general formula (1) in which the bonding ratio of three-branched polyethylene glycol (PEG) and G-CSF is 1:1 (mol/mol), wherein PEG has an average molecular weight of from 200 to 45,000 daltons; a pharmaceutical composition comprising the same, and a preparing method thereof.
摘要翻译： 本发明涉及三分支PEG-G-CSF缀合物，其中三分支聚乙二醇（PEG）和G-CSF的键合比为1:1（mol / mol），其中PEG 平均分子量为200至45,000道尔顿; 包含其的药物组合物及其制备方法。
-
7.发明申请Agent Comprising Fgf2 as an Effective Ingredient For Treatment or Prevention of Asthma and Chronic Obstructive Pulmonary Disease 有权包含Fgf2作为治疗或预防哮喘和慢性阻塞性肺疾病的有效成分的药剂公开(公告)号：US20080172751A1
公开(公告)日：2008-07-17
申请号：US11568896
申请日：2005-05-12
申请人： Yoon-Keun Kim , Soo Hyung Kang , Byong Moon Kim , Miwon Son
发明人： Yoon-Keun Kim , Soo Hyung Kang , Byong Moon Kim , Miwon Son
IPC分类号： A01K67/00 , A61K38/18 , A61P11/06 , A61K31/713
CPC分类号： A01K67/0275 , A01K2207/05 , A01K2207/10 , A01K2217/07 , A01K2217/203 , A01K2227/105 , A01K2267/0368 , A61K38/1825 , C07K14/52 , C07K14/5437 , C07K14/57 , C12N15/8509
摘要： The present invention relates an agent comprising FGF2 (Fibroblast Growth Factor-2 or basic Fibroblast Growth Factor(bFGF)) as an effective ingredient for treatment or prevention of Asthma and Chronic Obstructive Pulmonary Disease(COPD). Also, The present invention relates Th1 asthma and COPD mouse animal model induced by Ovalbumin and double strand RNA. The therapeutic agent comprising FGF2 of the present invention can be used for treatment or prevention for airway fibrosis, airway inflammation, airway hyperresponsiveness, airway remodeling, asthma and COPD. Also, Th1 asthma and COPD mice animal model induced by Ovalbumin and double strand RNA can be used for development of therapeutic agent for asthma and COPD.
摘要翻译： 本发明涉及包含FGF2（成纤维细胞生长因子-2或碱性成纤维细胞生长因子（bFGF））作为治疗或预防哮喘和慢性阻塞性肺疾病（COPD）的有效成分的药剂。 此外，本发明涉及由卵白蛋白和双链RNA诱导的Th1哮喘和COPD小鼠动物模型。 包含本发明的FGF2的治疗剂可用于治疗或预防气道纤维化，气道炎症，气道高反应性，气道重塑，哮喘和COPD。 此外，Th1哮喘和COPD小鼠由卵白蛋白和双链RNA诱导的动物模型可用于开发哮喘和COPD治疗剂。
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.018 秒)
